World Belief Asset Administration LLC lowered its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 19.0% throughout the third quarter, Holdings Channel stories. The fund owned 6,239 shares of the corporate’s inventory after promoting 1,462 shares throughout the quarter. World Belief Asset Administration LLC’s holdings in Johnson & Johnson have been value $1,011,000 as of its most up-to-date SEC submitting.
A number of different hedge funds have additionally modified their holdings of JNJ. Mcdaniel Terry & Co. raised its stake in Johnson & Johnson by 2.0% within the third quarter. Mcdaniel Terry & Co. now owns 185,003 shares of the corporate’s inventory valued at $29,982,000 after shopping for a further 3,571 shares within the final quarter. Assenagon Asset Administration S.A. raised its stake in Johnson & Johnson by 8.2% within the third quarter. Assenagon Asset Administration S.A. now owns 87,476 shares of the corporate’s inventory valued at $14,176,000 after shopping for a further 6,642 shares within the final quarter. Mowery & Schoenfeld Wealth Administration LLC raised its stake in Johnson & Johnson by 58.7% within the third quarter. Mowery & Schoenfeld Wealth Administration LLC now owns 246 shares of the corporate’s inventory valued at $40,000 after shopping for a further 91 shares within the final quarter. Mason & Associates Inc raised its stake in Johnson & Johnson by 14.3% within the third quarter. Mason & Associates Inc now owns 1,811 shares of the corporate’s inventory valued at $293,000 after shopping for a further 227 shares within the final quarter. Lastly, Jackson Wealth Administration LLC acquired a brand new stake in Johnson & Johnson within the third quarter valued at $220,000. 69.55% of the inventory is at the moment owned by institutional buyers and hedge funds.
Insider Shopping for and Promoting at Johnson & Johnson
In different Johnson & Johnson information, VP Robert J. Decker bought 5,635 shares of Johnson & Johnson inventory in a transaction that occurred on Friday, August thirtieth. The inventory was bought at a mean value of $165.06, for a complete worth of $930,113.10. Following the sale, the vice chairman now owns 18,973 shares of the corporate’s inventory, valued at roughly $3,131,683.38. The commerce was a 0.00 % lower of their place. The sale was disclosed in a doc filed with the Securities & Change Fee, which may be accessed by means of the SEC web site. 0.16% of the inventory is owned by company insiders.
Johnson & Johnson Inventory Efficiency
NYSE JNJ opened at $160.88 on Friday. Johnson & Johnson has a 52-week low of $143.13 and a 52-week excessive of $168.85. The enterprise’s 50-day transferring common value is $163.38 and its 200 day transferring common value is $154.98. The agency has a market cap of $387.28 billion, a P/E ratio of 23.28, a P/E/G ratio of two.90 and a beta of 0.52. The corporate has a fast ratio of 0.85, a present ratio of 1.07 and a debt-to-equity ratio of 0.44.
Johnson & Johnson (NYSE:JNJ – Get Free Report) final introduced its quarterly earnings knowledge on Tuesday, October fifteenth. The corporate reported $2.42 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a return on fairness of 35.46% and a web margin of 19.14%. The corporate had income of $22.47 billion for the quarter, in comparison with analyst estimates of $22.17 billion. Throughout the identical quarter within the earlier 12 months, the corporate earned $2.66 EPS. The agency’s income for the quarter was up 5.2% in comparison with the identical quarter final 12 months. On common, equities analysis analysts anticipate that Johnson & Johnson will publish 9.94 earnings per share for the present 12 months.
Johnson & Johnson Broadcasts Dividend
The agency additionally not too long ago disclosed a quarterly dividend, which will probably be paid on Tuesday, December tenth. Shareholders of file on Tuesday, November twenty sixth will probably be issued a $1.24 dividend. This represents a $4.96 dividend on an annualized foundation and a yield of three.08%. The ex-dividend date of this dividend is Tuesday, November twenty sixth. Johnson & Johnson’s dividend payout ratio is presently 71.78%.
Wall Avenue Analysts Forecast Development
JNJ has been the subject of a variety of analyst stories. Wells Fargo & Firm raised their value goal on Johnson & Johnson from $163.00 to $166.00 and gave the corporate an “equal weight” ranking in a analysis notice on Wednesday, October sixteenth. Morgan Stanley raised their value goal on Johnson & Johnson from $169.00 to $175.00 and gave the inventory an “equal weight” ranking in a report on Wednesday, October sixteenth. Daiwa America lowered Johnson & Johnson from a “strong-buy” ranking to a “maintain” ranking in a report on Tuesday, July twenty third. The Goldman Sachs Group dropped their value goal on Johnson & Johnson from $160.00 to $155.00 and set a “impartial” ranking on the inventory in a report on Friday, July nineteenth. Lastly, StockNews.com raised Johnson & Johnson from a “purchase” ranking to a “strong-buy” ranking in a report on Saturday, September 14th. Six equities analysis analysts have rated the inventory with a maintain ranking, seven have given a purchase ranking and one has assigned a robust purchase ranking to the corporate’s inventory. In keeping with knowledge from MarketBeat.com, the corporate at the moment has a mean ranking of “Average Purchase” and a mean value goal of $175.93.
Test Out Our Newest Analysis Report on JNJ
Johnson & Johnson Profile
Johnson & Johnson, along with its subsidiaries, researches, develops, manufactures, and sells numerous merchandise within the healthcare subject worldwide. The corporate’s Progressive Medication section affords merchandise for numerous therapeutic areas, equivalent to immunology, together with rheumatoid arthritis, psoriatic arthritis, inflammatory bowel illness, and psoriasis; infectious illnesses comprising HIV/AIDS; neuroscience, consisting of temper issues, neurodegenerative issues, and schizophrenia; oncology, equivalent to prostate most cancers, hematologic malignancies, lung most cancers, and bladder most cancers; cardiovascular and metabolism, together with thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension by means of retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Featured Articles
Need to see what different hedge funds are holding JNJ? Go to HoldingsChannel.com to get the newest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Obtain Information & Scores for Johnson & Johnson Each day – Enter your e-mail deal with beneath to obtain a concise day by day abstract of the newest information and analysts’ rankings for Johnson & Johnson and associated firms with MarketBeat.com’s FREE day by day e-mail e-newsletter.
